中华老年心脑血管病杂志

[1] GBD 2021 Nervous System Disorders Collaborators. Global, regional, and national burden of disorders affecting the nervous system,1990-2021:a systematic analysis for the Global Burden of Disease Study 2021[J]. Lancet Neurol, 2024, 23(4):344-381. DOI:10.1016/S1474-4422(24)00038-3.

[2] Zhang C, Yang X, Wan D, Ma Q, et al. Burden of neurological disorders in China and its provinces, 1990-2021:findings from the global burden of disease study 2021[J]. Med, 2025, 6(8):100692. DOI:10.1016/j.medj.2025.100692.

[3] Su D, Cui Y, He C, et al. Projections for prevalence of Parkinson's disease and its driving factors in 195 countries and territories to2050:modelling study of Global Burden of Disease Study 2021[J].BMJ, 2025, 388:e080952. DOI:10.1136/bmj-2024-080952.

[4] Parry-Jones AR, Krishnamurthi R, Ziai WC, et al. World Stroke Organization(WSO):Global intracerebral hemorrhage factsheet 2025[J]. Int J Stroke, 2025, 20(2):145-150. DOI:10.1177/17474930241307876.

[5] Wang S, Jiang Y, Yang A, et al. The expanding burden of neurodegenerative diseases:an unmet medical and social need[J]. Aging Dis,2024, 16(5):2937-2952. DOI:10.14336/AD.2024.1071.

[6]王华丽.精准医学时代老年精神医学研究发展机遇[J].中华精神科杂志，2025,58(3):197-201. DOI:10.3760/cma.j.cn113661-20241216-00426.

[7] Therriault J, Brum WS, Trudel L, et al. Blood phosphorylated tau for the diagnosis of Alzheimer’s disease:a systematic review and metaanalysis[J]. Lancet Neurol, 2025, 24(9):740-752. DOI:10.1016/S1474-4422(25)00227-3.

[8] Insel PS, Mattsson-Carlgren N, Langford O, et al. Concurrent changes in plasma phosphorylated tau 217, tau PET, and cognition in preclinical Alzheimer disease[J]. JAMA Neurol, 2025, 82(10):985-993. DOI:10.1001/jamaneurol.2025.2974.

[9] Arslan B, Brum WS, Pola I, et al. The impact of kidney function on Alzheimer’s disease blood biomarkers:implications for predicting amyloid-β positivity[J]. Alzheimers Res Ther, 2025, 17(1):48. DOI:10.1186/s13195-025-01692-z.

[10] Frisoni GB, Aho E, Brayne C, et al. Alzheimer’s disease outlook:controversies and future directions[J]. Lancet, 2025,406(10510):1424-1442. DOI:10.1016/S0140-6736(25)01389-3.

[11]中国老年医学学会认知障碍分会.认知障碍疾病基因诊断策略中国专家共识（2025版）[J].中华老年医学杂志，2025,44(9):1212-1225. DOI:10.3760/cma.i.issn.0254-9026.2025.09.002.

[12] van Olst L, Simonton B, Edwards AJ, et al. Microglial mechanisms drive amyloid-β clearance in immunized patients with Alzheimer’s disease[J]. Nat Med, 2025, 31(5):1604-1616. DOI:10.1038/s41591-025-03574-1.

[13] Negro G, Rossi M, Imbimbo C, et al. Investigating neuropathological correlates of hyperactive and psychotic symptoms in dementia:a systematic review[J]. Front Dement, 2025, 4:1513644. DOI:10.3389/frdem.2025.1513644.

[14] Chen Y, Cai J, She Y, et al. Long-term exercise enhances meningeal lymphatic vessel plasticity and drainage in a mouse model of Alzheimer’s disease[J]. Transl Neurodegener, 2025,14(1):37. DOI:10.1186/s40035-025-00497-2.

[15]王诗婵，商慧芳.帕金森病精准诊疗的现状和展望[J].中华神经科杂志，2023,56(5):469-475. DOI:10.3760/cma.j.cn113694-20221228-00977.

[16] Schr?ter N, Sajonz BEA, Jost WH, et al. Advanced therapies in Parkinson’s disease:an individualized approach to their indication[J]. J Neural Transm(Vienna), 2024, 131(11):1285-1293. DOI:10.1007/s00702-024-02773-3.

[17] Huang X, Wang Y, Xiang Y, et al. Genetic analysis of neurite outgrowth inhibitor-associated genes in Parkinson’s disease:a cross-sectional cohort study[J]. CNS Neurosci Ther, 2024,30(10):e70070. DOI:10.1111/cns.70070.

[18] Ben-Shlomo Y, Darweesh S, Llibre-Guerra J, et al. The epidemiology of Parkinson’s disease[J]. Lancet, 2024, 403(10423):283-292. DOI:10.1016/S0140-6736(23)01419-8.

[19] De Bartolo MI, Ojha A, Leodori G, et al. Association of early fMRI connectivity alterations with different cognitive phenotypes in patients with newly diagnosed Parkinson disease[J]. Neurology, 2025,104(1):e210192. DOI:10.1212/WNL.0000000000210192.

[20] Zhou ZD, Yi LX, Wang DQ, Lim TM, Tan EK. Role of dopamine in the pathophysiology of Parkinson’s disease[J]. Transl Neurodegener,2023, 12(1):44. DOI:10.1186/s40035-023-00378-6.

[21] Starr PA, Shivacharan RS, Goldberg E, et al. Five-year outcomes from deep brain stimulation of the subthalamic nucleus for Parkinson disease[J]. JAMA Neurol, 2025, 15:e253373. DOI:10.1001/jamaneurol.2025.3373.

[22] Zhao YC, Wu SQ, Li JK, et al. Predictive value of the combined triglyceride-glucose and frailty index for cardiovascular disease and stroke in two prospective cohorts[J]. Cardiovasc Diabetol, 2025,24(1):318. DOI:10.1186/s12933-025-02880-9.

[23] Feigin VL, Owolabi MO, World Stroke Organization–Lancet Neurology Commission Stroke Collaboration Group. Pragmatic solutions to reduce the global burden of stroke:a World Stroke Organization-Lancet Neurology Commission[J]. Lancet Neurol, 2023, 22(12):1160-1206.DOI:10.1016/S1474-4422(23)00277-6.

[24] Sarnowski C, Zhang Y, Ammous F, et al. Association of genetic scores related to insulin resistance with neurological outcomes in ancestrally diverse cohorts from the Trans-Omics for Precision Medicine(TOPMed)program[J]. Commun Biol, 2025, 8(1):1352. DOI:10.1038/s42003-025-08674-9.

[25] Tsoi KKF, Jia P, Dowling NM, et al. Applications of artificial intelligence in dementia research[J]. Camb Prism Precis Med, 2022, 1:e9.DOI:10.1017/pcm.2022.10.

[26] Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care:2020 report of the Lancet Commission[J]. Lancet, 2020, 396(10248):413-446. DOI:10.1016/S0140-6736(20)30367-6.

[27] Kale M, Wankhede N, Pawar R, et al. AI-driven innovations in Alzheimer’s disease:integrating early diagnosis, personalized treatment,and prognostic modelling[J]. Ageing Res Rev, 2024, 101:102497.DOI:10.1016/j.arr.2024.102497.